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Myf5 is a member of the muscle-speciﬁc determination genes and plays a critical role in skeletal muscle
development. Whereas the expression of Myf5 during embryonic and fetal myogenesis has been
extensively studied, its expression in progenitors that will ultimately give rise to adult satellite cells,
the stem cells responsible for muscle repair, is still largely unexplored. To investigate this aspect, we have
generated a mouse strain carrying a CreER coding sequence in the Myf5 locus. In this strain, Tamoxifen-
inducible Cre activity parallels endogenous Myf5 expression. Combining Myf5CreER and Cre reporter
alleles, we were able to evaluate the contribution of cells expressing Myf5 at distinct developmental
stages to the pool of satellite cells in adult hindlimb muscles. Although it was possible to trace back the
origin of some rare satellite cells to a subpopulation of Myf5+ve progenitors in the limb buds at the late
embryonic stage (∼E12), a signiﬁcant number of satellite cells arise from cells which expressed Myf5 for
the ﬁrst time at the fetal stage (∼E15). These studies provide direct evidence that adult satellite cells
derive from progenitors that ﬁrst express the myogenic determination gene Myf5 during fetal stages of
myogenesis.
Published by Elsevier Inc.Introduction
Skeletal muscle is the most abundant tissue in the vertebrate
body and plays a major role in physiological functions such as
locomotion, breathing and energy metabolism. When damage is
induced by injury or pathological conditions such as in the
muscular dystrophies, skeletal muscle manifests a powerful regen-
erative response (Dhawan and Rando, 2005; Kuang and Rudnicki,
2008; Zammit et al., 2006). Satellite cells are considered the main
stem cells responsible for adult muscle repair (Zammit et al.,
2006). They owe their name to their location beneath the basal
lamina in strict contact with muscle ﬁbers (Mauro, 1961), and they
are characterized by the expression of Pax7 (Seale et al., 2000).
Recent studies relying on the speciﬁc ablation of Pax7-expressing
cells in adult muscle demonstrate the requirement for satelliteInc.
ivated cell sorting;
myogenic regulatory factors;
ool of Medicine, Department
A-343, Stanford,cells to achieve a productive regenerative response (Lepper et al.,
2011; Murphy et al., 2011; Sambasivan et al., 2011). Upon muscle
injury, satellite cells enter into the cell cycle, rapidly up-regulate
the expression of myogenic regulatory factors (MRFs) such as Myf5
and MyoD, and terminally differentiate, ultimately fusing to form
regenerating ﬁbers. A fraction of activated satellite cells do not
undergo myogenic differentiation but instead self-renew, thereby
restoring the pool of quiescent satellite cells (Zammit et al., 2004).
Skeletal muscle formation occurs in several steps. Mesoderm-
derived precursors become speciﬁed to the myogenic lineage, and
these develop into myoblasts which become post-mitotic and
differentiate by fusing into multinucleated ﬁbers, expressing a
set of myoﬁbrillar proteins required for contraction. MRFs are key
regulators of the myogenic program. In vertebrates, four MRFs
have been identiﬁed: Myf5, MyoD, Mrf4, and Myogenin (Pownall
et al., 2002). MRFs are speciﬁcally expressed in the skeletal muscle
lineage and when transfected in certain other cellular types can
induce them to adopt a myogenic fate (Weintraub et al., 1989).
Myf5 is the ﬁrst of the MRFs to be expressed during mammalian
development (Ott et al., 1991). Mouse strains in which the
expression of Myf5, MyoD or Mrf4 was individually genetically
ablated present only relatively mild developmental phenotypes
(Braun et al., 1992; Kassar-Duchossoy et al., 2004; Rudnicki et al.,
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lack skeletal muscle in any anatomical location (Kassar-Duchossoy
et al., 2004; Rudnicki et al., 1993).Myogenin−/−mice form Myf5 and
MyoD expressing muscle progenitors, but are deﬁcient in differ-
entiated muscle (Hasty et al., 1993; Nabeshima et al., 1993).
Moreover, mice in which the expression of Mrf4, MyoD and
Myogenin are simultaneously abolished present normal numbers
of progenitors, but fail to form any differentiated muscle ﬁbers
(Valdez et al., 2000). Together, these observations and related cell
ablation studies (Haldar et al., 2008) suggest that Myf5 and MyoD
can independently initiate the myogenic program and thus act as
myogenic determination genes. The role of Mrf4 is more ambig-
uous, as it seems to act as determination gene only during
embryonic development (Kassar-Duchossoy et al., 2004).
In contrast, Myogenin appears to operate downstream to the
muscle determination genes by promoting muscle differentiation,
a role that Myf5 cannot play alone (Valdez et al., 2000).
Pax3 and its paralogue Pax7 have been suggested to promote
the progression of somitic progenitors into the myogenic lineage
(Buckingham and Relaix, 2007). In contrast to MRFs, Pax3 and
Pax7 are not muscle speciﬁc genes as they are expressed also in
the developing central nervous system, in the neural crest cells
and in the paraxial mesoderm before the establishment of deﬁni-
tive myogenic lineage (Buckingham and Relaix, 2007). Neverthe-
less, both Pax3 and Pax7 can enhance the myogenic potential of ES
cells (Darabi et al., 2008; Darabi et al., 2011). Furthermore, ectopic
Pax3 is able to induce MyoD and Myf5 expression in embryonic
mesoderm (Maroto et al., 1997) and ablation studies indicate that
Pax3 can act upstream of MyoD (Tajbakhsh et al., 1997).
Skeletal muscle is established in successive, though overlap-
ping, phases involving different types of myoblasts (embryonic,
fetal, and postnatal) which present distinct features (Biressi et al.,
2007a; Murphy and Kardon, 2011; Stockdale, 1992; Tajbakhsh,
2005). Muscle formation (with the exception of the early myo-
tome) has been attributed to a population of progenitors which are
dependent on the expression of Pax3 and Pax7 (Kassar-Duchossoy
et al., 2005; Relaix et al., 2005). These progenitors, initially not
expressing MRFs, can induce the myogenic program and differ-
entiate into skeletal muscle ﬁbers during primary (E10.5–E12.5)
and secondary (E14.5–E17.5) myogenesis or possibly remain as a
reserve cell population within the growing muscles during peri-
and postnatal stages (Kassar-Duchossoy et al., 2005; Relaix et al.,
2005).
Limb satellite cells are believed to derive from Pax3+ve cells,
which migrate from the dermomyotome into the developing limbs
(Schienda et al., 2006). They are initially negative for Pax7, but
they subsequently become dependent on Pax7 expression
(Hutcheson et al., 2009; Kassar-Duchossoy et al., 2005; Lepper
et al., 2009; Relaix et al., 2005, 2006; Seale et al., 2000). A lineage
study traced the origin of some adult limb satellite cells back to
cells expressing Pax7 at E11.5 (Lepper and Fan, 2010). In contrast to
the idea that adult satellite cells derive from MRF−ve precursors
resident in the postnatal muscle, a recent study suggests that great
majority, if not all adult satellite cells transit through a develop-
mental stage in which the MyoD locus is active (Kanisicak et al.,
2009). Nevertheless, the developmental stage at which the pre-
cursors of satellite cells ﬁrst express muscle determination genes
is unknown. Understanding this aspect is crucial to clarify the
relationship that the precursors of satellite cells have with myo-
genic cells involved in embryonic, fetal and postnatal muscle
growth.
In the present study, we generated a novel Tamoxifen-inducible
Myf5CreER mouse line, which allowed us to monitor the fate of cells
expressing Myf5 at different developmental stages. Using in vivo
and in vitro analyses relying on this and other muscle-speciﬁc Cre
lines, we investigated the developmental time at which theprecursors of satellite cells enter the myogenic program by
inducing the expression of the early muscle determination gene
Myf5, expanding our knowledge of the embryonic origin of adult
satellite cells.Materials and methods
Mouse strains and Tamoxifen (TMX) treatments
For the Myf5CreER mouse line, a targeting vector was con-
structed that placed an ires-CreER™-FRT-Neo-FRT cassette in the
AseI site within the 3′ untranslated region of the Myf5 gene
following the stop codon in exon 3. The ires-CreER™-FRT-Neo-
FRT cassette has been previously described (Nishijo et al., 2009).
This strategy and integration site is identical to the previously
reported non-inducible Cre mouse line (Haldar et al., 2007).
The linearized targeting vector was electroporated into R1 mouse
embryonic stem (ES) cells, and the cells were subjected to positive
selection with 200 μg/ml neomycin and negative selection with
2 μM ganciclovir. To detect positive clones upon screening, an
EcoRV site was engineered within the FRT-ﬂanked Neo cassette
(Keller et al., 2004a). Positive ES cell clones were detected by
EcoRV restriction endonuclease digestion of genomic DNA and
Southern hybridization with a 900 base pair (bp) 3′ external probe
ampliﬁed using PCR primers 5′-TGA ACA AGA AGG AAA GTG AGA
AAG G-3′ and 5′-CGT CAT GAC CTG AGA AGA GGA A-3′. Cells from
the identiﬁed ES cell clone were microinjected into C57BL/6
blastocysts in order to generate chimeric mice. Chimeric mice
were mated to C57BL/6 dams, and their agouti offspring were
conﬁrmed to harbor the targeted allele by Southern hybridization
(data not shown).
Myf5CreER/wt males were crossed to females carrying the repor-
ter alleles R26RLacZ (Soriano, 1999) or R26RYFP (Srinivas et al., 2001)
(Gt(ROSA)26Sortm1Sor/J and Gt(ROSA)26Sortm1(EYFP)Cos/J, respec-
tively, Jackson laboratories, Bar Harbor, ME). For the experiments
involving R26RLacZ mice, TMX (Sigma-Aldrich, St. Louis, MO) was
dissolved in corn oil and pregnant mice were injected intraper-
itoneally with a single injection of 3 mg at E10.5 or two
consecutive injections at E10.5 (1.5 mg) and E11.5 (2 mg). For
experiments involving R26RYFP, TMX (resuspended at 50 mg/ml
in 92.5% corn oil/7.5% ethanol) was administrated to pregnant
mice with different protocols relying on two injection in conse-
cutive days: E10.5 (5 mg)+E11.5 (5 mg); E12.5 (7.5 mg)+E13.5
(10 mg); E14.5 (7.5 mg)+E15.5 (10 mg). Newborn mice were
injected subcutaneously with 0.5 mg TMX for ﬁve consecutive
days from P7 to P11. Four-week-old mice were injected intraper-
itoneally with 2 mg TMX once a day for 5 days. Adult Pax7-CreERtm
mice (Nishijo et al., 2009) (herein referred to as Pax7CreER/wt)
received the same TMX regimen. MCre+/− (Brown et al., 2005),
Myf5-NN+/− (Haldar et al., 2008) and Pax7ICNm/wt (Keller et al.,
2004b) (herein referred to asMyf5Cre/wt and Pax7Cre/wt respectively)
males were crossed to R26RYFP/YFP, R26RLacZ/LacZ or Z/RED+/−
(Vintersten et al., 2004) female mice. To generate the Myf5CreER-
NNstrain, the FRT-ﬂanked Neo cassette was removed by breeding
Myf5CreER/wt mice to transgenic mice ubiquitously expressing
Flippase (Flpe) (B6.129S4-Gt(ROSA)26Sortm1(FLP1)Dym/RainJ, Jackson
laboratories).
The genotype of breeders and experimental animals was
identiﬁed by PCR on genomic DNA obtained by yolk sacs (prenatal)
or tail clips (postnatal). Gene-targeted Myf5CreER mice were geno-
typed by PCR using the primer set: ck172: 5′-GGA TAG TGA AAC
AGG GGC AA-3′, ck382: 5′-ACC CTC CAG CTC CAG ACT TAT C-3′,
ck383: 5′-CCC TGT AAT GGA TTC CAA GCT G-3′, and ck224: 5′-ACA
CTG CTC GAT GAA GTT CC-3′. Cycling conditions were: 95 1C for
5 min, 32 cycles of 95 1C for 30 s/59 1C for 30 s/72 1C for 120 s,
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Myf5Cre alleles resulted in 454, 182, or 312 bp bands, respectively.
Other strains were genotyped with published primers or with
primers speciﬁc to the Cre transgene: cF:,5′-GCA TTT CTG GGG ATT
GCT TA-3′, cR: 5′-CCC GGC AAA ACA GGT AGT TA-3′. Vaginal plug
day and the ﬁrst postnatal day are respectively designated as E0.5
and P1. Animal procedures were approved by the Institutional
Animal Care and Use Committees.
Xgal staining and whole-mount in situ hybridization
For Xgal staining, single ﬁbers were ﬁxed for 5 min in 2%
paraformaldehyde, permeabilized in PBS supplemented with 0.2%
(V/V) Triton X-100, treated with DAPI (Invitrogen) to stain the
nuclei and incubated for 2 days in Xgal solution (1 mg/ml
5-bromo-4-chloro-3-indolyl-β-D-galactosidase, 5 mM K4Fe(CN)6,
5 mM K3Fe(CN)6, 0.02% NP-40, 2 mM MgCl2 in PBS). Muscle
cryostat sections (12 μM) were processed for immunoﬂuroescence
and subsequently incubated in Xgal solution for 2 days, washed in
PBS and mounted in Fluorogel (EMS, Hatﬁeld, PA). For whole-
mount Xgal staining, embryos were ﬁxed for 5 h in 2% parafor-
maldehyde at 4 1C and incubated overnight at 37 1C in Xgal
solution as previously described (Biressi et al., 2008).
E11.5 embryos were processed for whole-mount in situ hybri-
dization with published probes (Kassar-Duchossoy et al., 2004), as
previously described (Biressi et al., 2008).
Cell isolation, ﬂuorescence activated cell sorting (FACS) and muscle
injury
Cells were isolated by enzymatic digestion from the hindlimbs
of developing and adult mice as previously described (Biressi et al.,
2007b; Bjornson et al., 2012). Brieﬂy, dissected adult hindlimb
muscles were digested in 0.2% type II collagenase in Ham's-F10
medium (Cellgro, Mediatech, Manassas, VA) for 70 min at 37 1C,
followed by a second digest in 1% dispase/0.2% type II collagenase
for 30 min at 37 1C (all enzymes from Invitrogen). Satellite cells
were mechanically dissociated from myoﬁbers after the ﬁnal
digestion by passing the tissue suspension through a 20-gauge
needle. Developing hindlimbs were dissociated with 0.15 mg/ml
collagenase Type V (Sigma), 0.4 mg/ml dispase, 0.1 mg/ml DNase I
(Worthington) in a buffered solution (Hank's Balanced Salt Solu-
tion (HBSS; BioWhittaker) supplemented with 15 mM HEPES,
15 mM glucose, 1.5 mM MgSO4, 0.3% (W/V) bovine serum albumin
(BSA), pH 7.4) for 45 min at 37 1C and ﬁltered on 40 μm cell
strainers (Falcon).
FACS analysis of adult satellite cells was performed as
previously described (Bjornson et al., 2012). Brieﬂy, satellite cells
were further puriﬁed using a FACSAria III (BD Biosciences, San Jose,
CA). Primary antibodies used were rat anti-CD31 conjugated to
allophycocyanin (APC; 1:100, BD Biosciences), rat anti-CD45
antibodies conjugated to allophycocyanin (APC; 1:100, BD
Biosciences), rat anti-Sca1 antibodies conjugated to Paciﬁc Blue
(1:100, BioLegend, San Diego, CA), biotinylated rat anti-CD106
antibody (VCAM; 1:100, BD Biosciences), phycoerythrin–Cy7
Streptavidin (1:100, BD Biosciences). DAPI dilactate (250 mg/ml,
Invitrogen) was used to exclude dead cells.
Cell suspensions obtained from Myf5Cre/wt or Pax7Cre/wt;
Z/RED+/− mice at different developmental stages were analyzed
and further puriﬁed using a Vantage Sorter SE (Becton Dickinson),
as previously described (Boutet et al., 2010). Forward scatter and
side scatter parameters were used to gate out cell clumps and
debris. Cells dissociated from DsRED−ve littermates were used as
negative controls to exclude autoﬂuorescent cells.
Cells isolated from postnatal muscles were resuspended in
Ham's F-10 supplemented with 10% horse serum (Invitrogen)and 20 mM HEPES. Cells adhered overnight on ECM-coated slides
(BioCoat BD) and ﬁxed for 5 min in 4% paraformaldehyde at 4 1C.
To test the proliferative and differentiation ability, cells were
cultured for 3 days in the same media. Prenatal myogenic cells
were alternatively resuspended in Opti-MEM (Invitrogen) supple-
mented with 20% FBS, 20 mM HEPES, and 5 ng/ml FGF (Peprotech)
to sustain proliferation or cultured for 3 days in a differentiation
permissive conditions consisting in Dulbecco's modiﬁed Eagle
medium, 20% horse serum, 20 mM HEPES. When indicated, 2 μM
cytochalasin D (Sigma) was added to the culture.
Tibialis anterior and gastrocnemious muscles were injured by
injecting 50 μl and 100 μl, respectively, of cardiotoxin (100 μg/ml,
Sigma).
Immunoﬂuorescent staining of ﬁbers, cultured cells and sections
Single ﬁbers were isolated and ﬁxed as previously described
(Bjornson et al., 2012). For immunoﬂuorescent staining, ﬁbers
were permeabilized in PBS supplemented with 0.1% (V/V) Triton
X-100 for 1 h and blocked in blocking solution (PBS, 1 mg/ml BSA,
1.5% donkey serum) for 40 min. Primary (overnight at 4 1C) and
secondary (45 min at room-temperature) antibody incubations
were performed in blocking solution with 0.1% Tween. Cells and
cryostat sections were processed as previously described (Biressi
et al., 2008). For immunohistochemistry of frozen adult skeletal
muscle, staining was performed using the M.O.M. Immunodetec-
tion Kit Staining Procedure (Vector Laboratories, Burlingame, CA)
or the Zenon Alexa Fluor 594 Labeling Kit (Life Technologies,
Grand Island, NY) following the manufacturer's instructions.
Primary antibodies used included rabbit anti-GFP (1:500, Invitro-
gen, Carlsbad, CA), chicken anti-GFP (1:500, Aves Labs, Tigard, OR
or Chemicon, Temecula, CA), rabbit anti-Desmin (1:500, Abcam,
Cambridge, MA), rabbit anti-Laminin (1:500, kindly provided by
Dr. Peter D. Yurchenco, University of Medicine and Dentistry of
New Jersey, NJ), rat anti-Laminin 2α (1:1000, Abcam), chicken anti-
Syn4 (1:200, kindly provided by Dr. Brad Olwin, University of
Colorado, Boulder), mouse anti-MyoD (1:100, Dako, Carpintaria,
CA), mouse anti-Myogenin (1:200, Becton/Dickson), mouse anti-
Pax7 (1:200, Developmental Studies Hybridoma Bank, Iowa City),
rabbit anti-Myf5 (1:100, Santa Cruz Biotechnology, Santa Cruz,
CA). Species-speciﬁc secondary antibodies (donkey) were conju-
gated to Alexa 488, 594, and 647 and used at a concentration of
1:1000 (Invitrogen). DAPI was added during the secondary anti-
body incubation to stain the nuclei.
Statistical analysis
Quantitative analyses were performed in at least 3 independent
replicates. Unless otherwise stated, data are expressed as mean
7standard deviation. Unpaired t-tests were used to evaluate the
statistical signiﬁcance between groups.Results
Myf5CreER mice present TMX-inducible Cre activity in the muscle
compartment
Limb satellite cells derive from Pax3+ve progenitors, which
migrate from the dermomyotome into the developing limb buds
(Schienda et al., 2006). As development proceeds, these progeni-
tors also express Pax7; this Pax+ve/MRFs−ve cell population is
detectable throughout development and is believed to give rise
to adult satellite cells (Kassar-Duchossoy et al., 2005; Relaix et al.,
2005). Interestingly, a recent study suggests that the great majority
of adult satellite cells are derived from precursors that express the
Fig. 1. Generation of Myf5CreER mice. (A) A targeting vector was designed for the insertion of a multifunctional cassette into the 3′ UTR of the Myf5 gene. At the AseI site in
exon 3, an IRES-CreER construct was inserted to allow bi-cistronic expression of Myf5 and CreER. An FRT-Neo-FRT cassette was inserted 3′ to IRESCreER. The positions of PCR
genotyping primers ck172, ck224, ck382 and ck383 are shown. Neo; neomycin resistance gene. Stop; stop codon. AseI; AseI restriction endonuclease site. (B) Southern blot
analysis of ES cell clones using a 3′ external probe. One correctly targeted clone (line 2) shows a band (asterisk), speciﬁc to the mutantMyf5CreER allele, which is 4 kb smaller
than the wild type band. (C) Genotyping PCR shows Myf5-CreER (182 bp), wild type (454 bp), and Myf5-ICNm (Haldar et al., 2007) (312 bp) alleles, respectively.
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However, the developmental time at which the precursors of the
satellite cells ﬁrst express one of the MRFs, at that point committing
to the myogenic lineage, remains unknown. To directly test this, and
also to assess whether satellite cell progenitors become committed
to the myogenic lineage during embryonic or fetal muscle growth,
we generated a mouse strain in which Cre could be inducibly
expressed from the Myf5 locus, as Myf5 is believed to be the ﬁrst of
the MRFs to be expressed during mouse development (Ott et al.,
1991). A targeting vector was constructed that placed an ires-
CreER™-FRT-Neo-FRT cassette within the 3′ untranslated region of
the Myf5 gene (Fig. 1A). A correctly targeted ES clone was identiﬁed
by a 4 kb decrease in electrophoretic mobility by Southern hybri-
dization using a 3′ external probe and DNA digestion by EcoRV
(Fig. 1B). Germline targeted mice harboring the engineered allele
were designated to have the genotypeMyf5CreER/wt. Genotyping PCR
was optimized to discriminate the Myf5CreER and the wild type
Myf5 loci (Fig. 1C). All progeny carrying the Myf5CreER allele were
found to be viable and fertile with no gross abnormalities.
In order to test the TMX-inducible Cre activity from the
engineered Myf5 locus, R26RLacZ/LacZ females were crossed with
Myf5CreER/wt males and received a single injection of TMX at 10.5
days postcoitum or consecutive injections at 10.5 and 11.5 days
postcoitum. Myf5CreER/wt; R26RLacZ/wt embryos were harvested
1 day after the end of the TMX treatment and were processed
for whole-mount Xgal staining. β-Galactosidase activity was evi-
dent in the myotomes of E11.5 embryos, paralleling the endogen-
ous expression of Myf5, and in the developing muscles of limbs,
the trunk and the head of E12.5 embryos (Fig. 2A). No expression
could be observed in the absence of TMX administration (Fig. 2A).
Immunostaining of E12.5 Myf5CreER/wt; R26RYFP/wt embryos treated
with TMX at E10.5 and E11.5 using antibodies recognizing YFP and
the myogenic marker Desmin showed that the YFP+ve cells
speciﬁcally localized to the myotome and to forming muscle
masses in the limbs (Fig. 2B). The pattern of YFP expression
resembled that observed in non-inducible Myf5Cre/wt; R26RYFP/wt
embryos, although the number of marked cells was higher in the
latter (Fig. 2C).
To determine if the expression of Cre-recombinase from the
engineered Myf5 locus paralleled the endogenous expression of
Myf5 in adult muscles, we administered TMX intraperitoneally to
4-week-old Myf5CreER/wt; R26RYFP/wt mice. Myf5 is expressed at
variable levels among adult quiescent satellite cells (Beauchamp
et al., 2000; Gayraud-Morel et al., 2012). Tibialis anterior muscles
were harvested for immunohistochemistry 2 weeks after the
beginning of the TMX treatment. Muscle satellite cells, deﬁnedas Pax7+ve cells localized beneath the ﬁber basal laminae, were
assessed for YFP expression (Fig. 2D). Out of 96 Pax7+ve satellite
cells counted, YFP expression was detected in 71. To conﬁrm the
muscle speciﬁcity of the Myf5CreER allele, other organs, including
brain (cerebrum and cerebellum), liver, kidney, spleen, and testis,
from TMX-treated Myf5Cre/wt; R26RYFP/wt mice were also examined
for YFP expression. YFP expression was not detectable in any of
those tissues. In order to test if the Myf5CreER allele could induce
recombination independently of TMX, muscle sections from
Myf5CreER/wt; R26RYFP/wt mice without TMX administration were
analyzed by immunoﬂuorescence. In those animals, YFP expres-
sion was not detected in any of the 46 Pax7+ve satellite cells
examined (Fig. 2D), suggesting a tight regulation by TMX of the
recombinase activity in the Myf5CreER strain. The leakiness in
absence of TMX was further quantiﬁed on cells isolated by
enzymatic digestion from adult hindlimb muscles. Only one YFP+ve
cell was observed when 2084 myogenic cells were analyzed
(∼0.05%, Suppl. Table 2). Moreover YFP was not detected by
immunoﬂuorescence in any other cells in the tissue, again indicat-
ing a high speciﬁcity of the Myf5CreER locus. We then compared
the lineage tracing of the Myf5CreER allele to that of the consti-
tutively active Myf5Cre allele. To determine the percentage of
satellite cells in the Myf5 lineage using a Myf5Cre allele con-
structed nearly identically to the Myf5CreER allele, tibialis anterior
muscles from age-matchedMyf5Cre/wt; R26RYFP/wt mice were exam-
ined (Fig. 2E). YFP expression was detected in 37 out of 39 Pax7+ve
satellite cells (95%). Together, these data demonstrate that the
pattern of Cre expression in the Myf5CreER mice accurately reﬂects
the activity of the Myf5 locus in muscles during embryonic
development and postnatally.
Myf5CreER activity can be used to mark Myf5-expressing cells
at different developmental stages
Different muscle groups exhibit different growth kinetics and
distinct developmental myogenic programs (Biressi et al., 2007a).
We decided to focus our attention on the muscles of hindlimbs,
which represent the muscles in which satellite cells are most
commonly studied. We compared different regimens of TMX
administration in terms of kinetics and dosage in order to optimize
Cre-mediated recombination in myogenic cells. To address this,
R26RLacZ/LacZ females were crossed with Myf5CreER/wt males and
given either a single injection of TMX at E10.5 or two consecutive
injections at E10.5 and E11.5 to induce the expression of the
reporter gene. E16 fetuses were collected and processed for
whole-mount Xgal staining. Whereas both TMX administration
Fig. 2. Characterization of Myf5CreER mice. (A) Whole-mount Xgal staining of Myf5CreER/wt; R26RLacZ/wt embryos. TMX administration protocols and stages as indicated.
Myf5CreER/wt; R26RLacZ/wt embryos injected with corn oil were used as negative controls. Whole-mount in situ hybridization (ISH) of E11.5 embryos with Myf5-speciﬁc probes
is shown to highlight the pattern of Myf5 expression. Arrows mark the myotomes. Bar, 1 mm. (B) Transverse sections of Myf5CreER/wt; R26RYFP/wt E12.5 embryos treated with
TMX (5 mg) at E10.5 and E11.5 were stained with antibodies recognizing YFP and Desmin. DAPI was used to stain the nuclei. YFP+ve cells localize to the myotome (M;
Desmin+ve) lateral to the neural tube (NT) and in the forming muscle masses in the forelimbs. Bar, 50 μm. (C) Sections of the limb of E12.5Myf5Cre/wt; R26RYFP/wt are shown as
term of comparison. Bar, 50 μm. (D) Immunoﬂuorescence analysis of skeletal muscle from adult Myf5CreER/wt; R26RYFP/wt mice 2 weeks after TMX injections, or without TMX
administration. Bar, 100 μm. (E) Immunoﬂuorescence analysis of skeletal muscle from Myf5Cre; R26RYFP/wt mice. Frozen sections of tibialis anterior muscles were
immunostained for YFP, Pax7, and Laminin. Nuclei were counterstained with DAPI. Yellow arrows point to YFP+ve satellite cells (D, E). A white arrow on the merged
image shows a YFP−ve satellite cell localized beneath the basal membrane (D).
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Fig. 3. Temporal control and efﬁciency of TMX-induced labeling in developingMyf5CreER mice. (A) Whole-mount Xgal staining ofMyf5CreER/wt; R26RLacZ/wt skinned E16 fetuses.
Alternative TMX administration protocols are indicated. Depending on the protocol used, Cre-mediated recombination was induced in the hindlimb muscles (dashed box) in
addition to forelimb muscles (arrows). Bar, 1.2 mm. (B) Cells are isolated from hindlimb muscles of Myf5CreER/wt; R26RYFP/wt mice treated with the indicated regimen of TMX
and sacriﬁced (Sac) at the indicated stages, and are stained with antibodies recognizing YFP and the myogenic markers Pax7, MyoD and Myogenin (Mgn). The labeling
efﬁciency is quantiﬁed by counting the number of myogenic cells (positive for Pax7, MyoD or Mgn) that are YFP+ve. Results are expressed as mean7standard deviation. The
labeling efﬁcacy detected at E16.5 is lower compared to that obtained postnatally and at earlier embryonic stages (*Po0.05; **Po0.01). (C) Representative images of cells
obtained from E16.5 fetuses and P12 pups treated with TMX at the indicated times are shown. Bar, 50 μm.
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forelimb muscles, only by administering TMX at E11.5 was robust
β-galactosidase activity detectable in hindlimb muscles (Fig. 3A),
probably reﬂecting the different activity of the Myf5 locus as
myogenesis is proceeding along a rostro-caudal gradient. This
observation indicates that injected TMX is effective for a narrow
window of time, allowing for tight temporal control of
Cre-mediated recombination in Myf5CreER mice.
In terms of dosage, we opted for two injections on consecutive
days with different amounts of TMX depending on the develop-
mental stage (embryonic: E10.5 (5 mg)+E11.5 (5 mg); early fetal:
E12.5 (7.5 mg)+E13.5 (10 mg); mid-fetal stage: E14.5 (7.5 mg)+E15.5
(10 mg)). Newborn mice were injected subcutaneously with 0.5 mg
TMX on ﬁve consecutive days from P7 to P11. Higher dosages caused
a high rate of lethality. The extent of labeling with these protocols
was evaluated on cells obtained by enzymatic digestion of the
hindlimb muscles from Myf5CreER/wt; R26RYFP/wt mice 1 day after
the end of the TMX treatment (Fig. 3B), and it ranged between
approximately 4% observed at the mid-fetal stage (Fig. 3C) to
approximately 10% at the neonatal stage (Fig. 3D and Suppl.
Table 1). The quantiﬁcation of YFP+ve cells in the absence of TMX
administration indicated a negligible TMX-independent recombina-
tion at all developmental stages evaluated (o0.1%, Suppl. Table 1).
Previous work showed that the removal of the Neomicin (Neo)
cassette from mice engineered to express Cre-recombinase under
the control of the Myf5 locus increased the labeling efﬁciency
when compared to the parental strain containing the Neo cassette
(Haldar et al., 2008). In order to maximize the number of cells we
are able to mark at fetal stage (the stage presenting minor
labeling), we excised the Neo cassette by breeding the Myf5CreER
line with a strain ubiquitously expressing Flippase-recombinase
(Suppl. Fig. 1A and B). We than evaluated the labeling efﬁciency on
myogenic cells isolated from the hindlimbs of E16.5 fetuses as
previously described for the mice containing the Neo cassette
(Suppl. Fig. 1C). At this stage we found only a slight increase in the
number of YFP+ve cells upon removal of the Neo cassette
(3.871.6% and 3.670.8% in absence and presence, respectively,
of the Neo cassette). This result suggests that, for the purposes of
this study, the strain without the Neo cassette does not present a
signiﬁcant advantage over the strain with the Neo cassette. Based
on this observation and our ﬁndings of the tissue-speciﬁcity of the
strain containing the Neo cassette (see above), we chose to use
these mice for further study.Myf5 expression during fetal myogenesis deﬁnes the progenitors of
the majority of adult satellite cells
The expression of the Cre-inducible reporter was detectable in
satellite cells from adult (42 months old) Myf5CreER/wt; R26RYFP/wt
mice treated with TMX at each developmental stage evaluated,
although the fraction of marked cells was low when TMX was
administrated before E14.5. Experiments with single ﬁbers from
EDL muscles of Myf5CreER/wt; R26RYFP/wt mice conﬁrmed the satel-
lite cell identity of marked cells by co-staining with antibodies
recognizing YFP and the satellite cell markers Pax7 and Syn4
(Fig. 4A). A similar result was obtained using β-galactosidase
(Fig. 4B). YFP+ve satellite cells were easy to identify when TMX
was administered after E14.5 (Fig. 4C). Interestingly, the adult EDL
myoﬁbers showed a weaker Xgal or YFP staining in comparison to
the associated satellite. There are at least two (non-mutually
exclusive) explanations for this observation. First, as the recombi-
nation of the R26R-YFP/LacZ locus in the Myf5CreER line is incom-
plete, it is expected that only a fraction of the myonuclei express
the reporter gene, therefore diluting the signal. Second, the Rosa26
locus, which drives the expression of the reporter genes upon Cre-
mediated recombination, could be less active in the terminally
differentiated ﬁber than in the satellite cells. This second hypoth-
esis is strongly supported by the observation that a very weak YFP
signal was also observed in ﬁbers compared to satellite cells when
highly efﬁcient Cre lines, such as the TMX-independent Myf5Cre
strain (see Fig. 2E), were used. In those strains in which virtually
all of the myonuclei would have recombined alleles, ﬁbers still
exhibit weak reporter gene expression from the Rosa26 locus.
Satellite cells can be prospectively isolated from cellular sus-
pensions of adult muscles according to the surface expression of
VCAM and the absence of CD45, CD31 and Sca1 (Bjornson et al.,
2012). FACS analysis can be therefore used to quantify the fraction
of the VCAM+ve/CD45−ve/CD31−ve/Sca1−ve satellite cells expressing
the lineage marker YFP. More satellite cells were labeled when
TMX injections in Myf5CreER/wt; R26RYFP/wt mice were performed at
the neonatal stage than at either the embryonic or fetal stages.
Moreover, TMX injection at the mid-fetal stage (E14.5–E15.5)
generated more labeled satellite cells, as assessed by FACS, than
TMX treatment at earlier stages (Fig. 4D). A similar trend was
conﬁrmed by quantifying the percentage of myogenic cells, which
were YFP+ve using immunoﬂuorescence microscopy (Fig. 4E, F, and
Suppl. Table 2). Notably, when the absolute numbers were
Fig. 4. Adult satellite cells derive from progenitors expressing Myf5 during prenatal development. (A) An example of a YFP+ve satellite cell (arrow) associated with an EDL
ﬁber of an adult Myf5CreER/wt; R26RYFP/wt mouse treated with TMX at E10.5–E11.5. Staining with antibodies recognizing YFP and the satellite cell markers Pax7 and Syn4 is
presented. Bar, 20 μm. (B) Xgal staining of an EDL ﬁber from an adultMyf5CreER/wt; R26RLacZ/wt mouse treated with TMX at E10.5–E11.5. A β-gal+ve satellite cell is shown (arrow
and insets). Bar, 30 μm. (C) An example of a satellite cell expressing the reporter gene YFP (arrowhead) after administration of TMX to E14.5–E15.5 is shown. Note that due to
the relatively low efﬁciency of recombination, most of the satellite cells are YFP−ve (asterisk). DAPI was used to stain the nuclei. Bar, 40 μm. (D) The fraction of the VCAM+ve/
CD45−ve/CD31−ve/Sca1−ve satellite cells expressing the lineage marker YFP (FITC) was quantiﬁed by FACS on cells obtained from adult Myf5CreER/wt; R26RYFP/wt mice after TMX
administration at different developmental stages, as indicated. Satellite cells from Pax7CreER/wt; R26RYFP/wt mice injected with TMX at adult stage were used as positive
controls. Note that the analysis of the satellite cells obtained from Myf5CreER/wt; R26RYFP/wt not treated with TMX reveals a virtual absence of recombination. (E) Cells were
isolated by enzymatic digestion from hindlimb muscles of Myf5CreER/wt; R26RYFP/wt mice treated with TMX at the indicated stages and allowed to adhere overnight in vitro.
Cells were then stained with an antibody to YFP and with a cocktail of antibodies to Pax7, MyoD, and Mgn to reveal the total pool of myogenic cells. Bar, 25 μm. (F) Data from
replicate studies shown in panel E were quantiﬁed to determine the percentage of myogenic cells that were marked by YFP. Results are expressed as mean7standard
deviation. The recombination obtained after TMX administration at E14.5–E15.5 or P7–P11 is signiﬁcantly higher compared that detected at earlier stages (**Po0.01,
*Po0.05). (G) Data from replicate studies shown in panel E were quantiﬁed to determine the percentage of myogenic cells that were marked by YFP and were normalized for
the average efﬁciency of recombination observed after TMX treatment at different stages (see Fig. 3B). Each square represents the normalized value obtained in a single
replicate (n¼3 for each condition). Note that a minority of satellite cells traces its origin back to progenitors expressing Myf5 at the embryonic (E10.5–E11.5) or early fetal
(E12.5–E13.5) stage, whereas 475% of the satellite cells derive from progenitors expressing Myf5 at the mid-fetal (E14.5–15.5) or neonatal (P7–11) stage.
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after TMX treatment at each stage (see Fig. 3B), the major
contribution to the adult satellite cell compartment is from cells
expressing Myf5 at the mid-fetal stage (E14.5–E15.5) (Fig. 4G).
These data suggest that it is at the mid-fetal stage that a large
fraction (475%) of the progenitors that will give rise to adult
satellite cells commit to the myogenic lineage by inducing Myf5
expression, and that only a minority initiate the myogenic pro-
gram
(as deﬁned by Myf5 expression) earlier during development
(Fig. 4G). The Myf5 locus remained active also in neonatal
progenitors and adult satellite cells (Figs. 2E and 4G).
We subsequently evaluated if satellite cells expressing Myf5
before adulthood could participate in muscle regeneration. To this
end, injury was induced by cardiotoxin injection into hindlimb
muscles of adult Myf5CreER/wt; R26RYFP/wt mice to which TMX has
been administered during the newborn period. Four days after
injury, the presence of labeled cells was evaluated by FACS
analysis. A roughly similar proportion of cells were labeled in
injured and uninjured muscles (Suppl. Fig. 2A and Fig. 4D),
suggesting that satellite cells expressing Myf5 before adulthood
can undergo a proliferative expansion upon injury. Moreover
labeled cells expressing the myogenic activation marker MyoD
and the differentiation marker Myogenin were rapidly identiﬁed
in injured muscles demonstrating their ability to progress into the
myogenic program in vivo (Suppl. Fig. 2B).
The early induction of Myf5 in the progenitors of satellite cells is
associated with the beginning of the fetal myogenic program in theFig. 5. Enrichment in cells of the Pax7-lineage in the limb muscles at the fetal stage.
Pax7Cre/wt; R26RLacZ/wt mice at the indicated developmental stages. Limbs are indicated w
muscles of Myf5Cre/wt; Z/RED+/− E12.5 embryos, cultured for 4 h in vitro in proliferating
antibodies recognizing Pax7 and Myf5. The percentage of Myf5+ve doublets (proliferatin
25 μm. (C) DsRED+ve cells obtained from the hindlimb muscles of Myf5Cre/wt; Z/RED+/− an
Data from the Pax7 line are expressed as percentage of DsRED+ve cells from the Myf5 llimb muscles
During limb muscle development Pax7+ve cells contribute
negligibly to embryonic myogenesis but in their absence fetal
myogenesis is dramatically compromised (Hutcheson et al., 2009).
Likewise, the comparison of the expression of β-galactosidase
induced in R26RLacZ/wt lines by the expression of Cre under the
control of regulatory sequences of Pax3 (Mcre), Myf5 and Pax7
clearly showed that Pax7 is induced for the ﬁrst time in progeni-
tors in the limbs only at the end of primary (embryonic) myogen-
esis (Fig. 5A). Pax7 expression became more robust during fetal
myogenesis (Fig. 5A).
It has been recently shown by in vivo lineage tracing that Pax7+ve
cells present in the developing limbs as early as the embryonic stage
E11.5 can give rise to adult satellite cells (Lepper and Fan, 2010). Our
data indicate that a minority of adult satellite cells derives from cells
expressing Myf5 during embryonic myogenesis (see above). Together
these observations raise the possibility that Pax7+ve/Myf5+ve cells in
the embryonic limbs could give rise to satellite cells. If this hypothesis
holds true, a population of Pax7+ve/Myf5+ve myoblasts which is
distinct from embryonic myoblasts (Pax7−ve) should be already
present in the embryonic limbs. To test this, we decided to quantify
the co-expression of Myf5 and Pax7 in myogenic progenitors at
E12.5, extending previous observations (Kassar-Duchossoy et al.,
2005). We puriﬁed myogenic cells from the hindlimb muscles of
E12.5 Myf5Cre/wt; Z/RED+/− embryos by FACS (Suppl. Figs. 3A and 2B)
(Boutet et al., 2010), and we quantiﬁed the percentage of Myf5+ve
cells co-expressing Pax7. We restricted the analysis to proliferating(A) Whole-mount Xgal staining of MCre+/−; R26RLacZ/wt, Myf5Cre/wt; R26RLacZ/wt and
ith arrows. Bar, 3 mm. (B) DsRED+ve cells were isolated by FACS from the hindlimb
conditions in presence of the cytokinesis blocker cytochalasin, and stained with
g myoblasts) positive (arrowhead) or negative (asterisk) for Pax7 is quantiﬁed. Bar,
d Pax7Cre/wt; Z/RED+/− mice at E12.5, E15.5 and adult stages were quantiﬁed by FACS.
ine at the same stage.
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the addition of cytochalasin. Under these conditions, ∼20% of the
Myf5+ve cells also expressed Pax7 (Fig. 5B). As we restricted the
analysis to proliferating cells, we can exclude the possibility that
Pax7−ve/Myf5+ve cells consist of differentiating cells, which have
already down-regulated Pax7 expression. Rather, the presence in
the pool of proliferating cells of Myf5-expressing cells, which are
alternatively Pax7+ve or Pax7−ve, suggest the co-existence of two
distinct populations in the hindlimbs at E12.5. As fetal, but not
embryonic, myogenesis in the hindlimbs is dependent on Pax7 (see
above), it is likely that the predominant population of Pax7−ve/
Myf5+ve cells consists of embryonic myoblasts, whereas the sub-
population of Pax7+ve/Myf5+ve cells could include early fetal myo-
blasts and the ancestors of the satellite cells. In keeping with this
idea, as development proceeds, the fraction of the hindlimb cells
marked by the Pax7Cre lineage tracer increases when compared to the
number of cells labeled in the Myf5Cre line (Fig. 5C), correlating with
the increased contribution to the satellite cell compartment by cells
expressing Myf5 at the mid-fetal stage (see above). Due to the
absence of tools that would allow us to genetically label cells that
are simultaneously expressing Myf5 and Pax7, we could not trace in
time the fate of the Pax7+ve/Myf5+ve cells. Nevertheless, the data
reported here suggest that some ancestors of the satellite cells are
part of the pool of the Pax7+ve/Myf5+ve cells present in the late
embryonic limbs and link the beginning of the fetal myogenic
program with the initial induction of Myf5 in the precursors of the
satellite cells.Discussion
Satellite cell ancestors and other myogenic precursors
Satellite cells in limb and body wall musculature, like embryo-
nic and fetal myoblasts, are somitic in origin (Armand et al., 1983;
Gros et al., 2005; Schienda et al., 2006). Satellite cell precursors
have been reported to express Pax3 and Pax7, but not MRFs
(Kassar-Duchossoy et al., 2005; Relaix et al., 2005). These Pax+ve/
MRF−ve precursors were observed throughout development from
early embryonic to postnatal stage. At the fetal stage, a fraction of
mononucleated Pax7+ve cells could be identiﬁed beneath the
ﬁbers' basal laminae, in the typical satellite cell position (Kassar-
Duchossoy et al., 2005). However, we have no data that indicates
the fate of these cells. Speciﬁcally, we do not know if they (or their
progeny) were destined to remain in the sublaminar position to
become the satellite cells in adult muscle, if they were destined to
fuse to growing myoﬁbers, or some combination of the two. It has
been suggested that Pax+ve/MRF−ve precursors could both give rise
to MRF+ve myoblasts and self-renew as MRF−ve cells (Kassar-
Duchossoy et al., 2005; Relaix et al., 2005). On the other hand,
a recent lineage study relying on mice expressing Cre-recombinase
under the control of the regulatory regions of MyoD suggests that
the great majority (∼98%) of satellite cells derive from cells
MyoD-expressing progenitors present pre- or peri-natally
(Kanisicak et al., 2009). Therefore, it remains unclear to what
extent the Pax+ve/MRF−ve population is a stable reservoir of MRF−ve
progenitors. Likewise, the lineage relationship between MRF−ve
precursors, developmental myoblasts and satellite cells remains
undetermined.
Skeletal muscle in mammals is formed through successive
phases of ﬁber formation involving different generations of myo-
blasts (embryonic, fetal, and postnatal) (Biressi et al., 2007a;
Murphy and Kardon, 2011; Stockdale, 1992; Tajbakhsh, 2005).
Myoblasts participating in skeletal muscle development are highly
heterogeneous in terms of morphology, differentiation kinetics,
response to growth factors, gene expression before and afterdifferentiation and active signaling pathways (Biressi et al.,
2007a). A genome-wide expression analysis carried out on myo-
blasts puriﬁed at embryonic and fetal stages strongly suggest that
they represent intrinsically distinct cell populations (Biressi et al.,
2007b). Furthermore, a speciﬁc myogenic program in fetal muscle
dependent on the Pax7-Nﬁx axis (Messina et al., 2010) and on Wnt
signaling (Hutcheson et al., 2009) was identiﬁed. Differences in the
ability to respond to chemicals in vitro have been reported
between fetal and postnatal myoblasts (Cossu et al., 1983). More-
over, a gene inactivation study revealed that Pax7 is required for
the regeneration of juvenile (before P21) but not adult muscles
(Lepper et al., 2009). These observations suggest that fetal myo-
blasts, neonatal myoblasts, and adult satellite cells could also be
intrinsically different lineages.
The observations presented here suggest that the majority of
adult satellite cell precursors express Myf5 at the fetal stage. Only
a minority (o25%) of satellite cell precursors had expressed Myf5
at the embryonic stage. Furthermore, we show here (Fig. 5) that
the early appearance of Myf5+ve satellite cell ancestors at embryo-
nic stages overlaps with the initial appearance of the fetal and
satellite cell marker Pax7 in the limbs (Hutcheson et al., 2009),
indicating that the activation of Myf5 expression in the precursors
of the satellite cells in the embryonic state could in fact be linked
with the beginning of fetal myogenesis. Intriguingly, recent studies
revealed the presence of non-cycling (Ki67−ve) Pax7+ve/Myf5+ve
cells at the fetal (E15) but not at the embryonic (E12) stage (Picard
and Marcelle, 2013). Based on the genetic models used in that
study, those investigators did not provide direct evidence that
these quiescent cells expressing Myf5 at the fetal stage could give
rise to the satellite cells in the adult. Nevertheless, those data
indirectly support the results presented here that adult satellite
cells preferentially derive from fetal Myf5+ve cells, whereas the
embryonic Myf5+ve cells have limited, if any contribution. There-
fore although the majority of fetal myoblasts is terminally differ-
entiating at the fetal stage, some of their progeny remain as
committed but undifferentiated cells until the end of development
to give rise to satellite cells. The mechanisms regulating this fate
decision are completely unknown and could possibly depend on
an intrinsic heterogeneity in the pool of fetal myoblasts. The
identiﬁcation of molecular markers (if they exist) that can be
employed to discriminate satellite cell precursors from other
lineages will possibly clarify this point in future.
A recent study demonstrates that pericytes resident in post-
natal growing muscle can contribute to the adult satellite cell pool
during normal growth (Dellavalle et al., 2011). The authors of this
study employed an alkaline phosphatase CreER mouse strain to
mark pericytes with an efﬁciency of ∼70%. They were able to trace
back to pericytes the origin of a fraction of satellite cells. Intrigu-
ingly, the contribution of pericytes to the satellite cell pool is
different in muscles with distinct developmental origins, ranging
from almost 25% in the pectoralis to less than 10% in the hindlimb
muscles. These results are not in contradiction with those reported
here, showing that a large number of the satellite cells resident in
adult hindlimb muscles derive from cells expressing Myf5 at a
fetal stage. Intriguingly it has been recently shown that a fraction
of pericytes transiently induce Myf5 during fetal development
(Cappellari et al., 2013). These pericytes are likely to maintain
myogenic features, as essentially all the YFP+ve cells we could
isolate from the Myf5CreER/wt; R26RYFP/wt hindlimb muscles treated
with TMX at different developmental stages expressed Pax7, MyoD
or Myogenin (Suppl. Table 3).
Over the past decade, other MRF−ve cells which have myogenic
potential but are distinct from satellite cells have been identiﬁed
during development or regeneration (Tedesco et al., 2010).
It has also been reported that some of them can give rise to
satellite cells and participate in muscle regeneration in
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challenged by injury or pathological conditions. However, it
remains unclear if they generate satellite cells during normal
development (Asakura et al., 2002; Dreyfus et al., 2004; LaBarge
and Blau, 2002; Mitchell et al., 2010; Sampaolesi et al., 2003;
Torrente et al., 2004). Understanding how these populations of
putative myogenic cells relate not only to adult satellite cells but
also to each other and to embryonic and fetal myoblasts from a
lineage point of view will be crucial for the comprehension of
skeletal muscle development.
Myf5-independent lineage and considerations related to
normalization
The pool of satellite cells is itself heterogeneous (Biressi and
Rando, 2010). Particularly relevant for the purposes of this study is
a report based on the use of a non-inducible Myf5Cre strain, which
shows that approximately 10% of the total population of adult
satellite cells associated with EDL ﬁbers do not appear to have a
history of Myf5 expression (Kuang et al., 2007). Intriguingly, Myf5
is actively expressed, although at varying levels, in approximately
90% of quiescent satellite cells resident in the adult muscles
(Beauchamp et al., 2000; Gayraud-Morel et al., 2012). A recent
report showed that approximately 98% of the satellite cells
associated with EDL ﬁbers expressed MyoD at some point in their
history before reaching adulthood (Kanisicak et al., 2009). These
observations suggest the possibility that a small fraction of
satellite cells could have a history of MyoD expression, but not
of Myf5 expression, in their ancestry. This idea is also supported by
the identiﬁcation through conditional ablation of Myf5 expressing
cells of a Myf5 independent lineage, which can participate in
muscle formation (Gensch et al., 2008; Haldar et al., 2008). For
obvious reasons, this small subpopulation of satellite cells would
not be the object of the lineage study presented here. Performing a
study similar to the one presented here, but employing an
inducible MyoDCreER strain, could possibly give insight as to when
this subpopulation of satellite cells is determined to the myogenic
lineage.
The data presented here suggest that most satellite cells
progenitors with a history of Myf5 expression have already
induced its expression by the fetal stage (Fig. 4G). This conclusion
depends on the normalization for the labeling efﬁciency we have
quantiﬁed in developmental cells (Fig. 3B).
Theoretically, there are limitations in this approach that could
lead to an over- or under-estimation of the proportion of satellite
cells derived from progenitors expressing Myf5 at a speciﬁc
developmental stage. First, the normalization we have used is
based on the assumption that the activity of theMyf5 locus is fairly
homogeneous in myogenic cells throughout development. Studies
employing the Myf5nLacZ mouse strain suggest that in the great
majority of Pax7+ve progenitors in the developing limbs, the Myf5
locus is transcriptionally active (Kassar-Duchossoy et al., 2005).
A recently published immunoﬂuorescence study suggests that the
fraction of Pax7+ve cells that co-express Myf5 protein, although
still representing the majority of the cells, could be reduced during
the fetal stage (Picard and Marcelle, 2013). These observations and
any possible future observation related to the assumptions made
for the normalization should be taken into account during the
interpretation of the model we are presenting here. Moreover, the
quantiﬁcation of the extent of labeling after TMX injections is
affected by a certain degree of variability, ranging from 5.8% to
8.3% at E10.5–11.5 from 4.6% to 5.9% at E12.5–13.5, from 3% to 4.5%
at E14.5–15.5, and from 5.6% to 12.5% at P7–P11. Furthermore, the
identiﬁcation of labeled cells relies on the productive excision of
the stop-sequence necessary for the induction of the reporter gene
and implies that the expression of the reporter gene from theRosa26 locus reaches detectable levels (Soriano, 1999; Srinivas
et al., 2001). To have an accurate quantiﬁcation of the efﬁciency of
labeling, the temporal window between TMX administration and
the analysis should allow for maximal recombination to occur. In
this study, labeling was quantiﬁed using cells isolated one day
after the end of the TMX treatment (see above). It is conceivable
that, under these conditions, our analysis could have missed some
late recombining cells. Nevertheless, several observations indicate
that they should represent only a small fraction of the marked
cells: (1) TMX has been reported to have a relatively short half-life
(t1/2o12 h) in mouse tissues (Robinson et al., 1991); (2) previous
studies relying on different CreER mouse lines indicate that most
of the recombination occurs in embryos between 12 and 24 h after
a single TMX injection to the pregnant mother (Hayashi and
McMahon, 2002; Nakamura et al., 2006); (3) after 24 h, the
nuclear accumulation of CreER is dramatically reduced and CreER
activity is negligible after 24–48 h depending on the experimental
setting, indicating that effective TMX levels are maintained for a
short time window in the embryonic circulation (Hayashi and
McMahon, 2002; Nakamura et al., 2006); (4) although the Myf5
locus is active from E11 onward in the hindlimbs (Ott et al., 1991),
we observed only rare labeled cells when a single dose of TMX was
administered the previous day, whereas an intense labeling was
observed in developing muscles after an additional TMX injection
at E11.5 (Fig. 3A). For these reasons, although it is possible that a
fraction of the satellite cell ancestors induce Myf5 expression for
the ﬁrst time after the fetal stage, the data presented here suggest
that the majority of them have already expressed Myf5 before
birth. Moreover, the quantiﬁcation of the efﬁciency of labeling was
performed in the same way at all developmental stages consid-
ered. Therefore, the normalized data reported here (Fig. 4G)
should truly reﬂect the dramatic increase (48-fold) in the induc-
tion of the myogenic program in satellite cell ancestors as devel-
opment proceeds from the embryonic to the fetal stage.
Applications of the Myf5CreER mouse
In this report, we describe studies using a novel mouse in
which the cDNA coding for a TMX-inducible CreER-recombinase is
inserted in the 3′ UTR of the Myf5 locus. We employed this strain
to genetically mark Myf5-expressing cells of the hindlimbs at
different developmental stages and to evaluate the contribution of
their progeny to the adult satellite cell compartment. There are,
however, many developmental studies for which this strain will be
of great value. For example, studies with mice expressing CreER
under the control of Pax7 (Lepper and Fan, 2010) and En1 (Atit
et al., 2006) suggest that the central dermomyotome contains
multi-potent progenitors for muscle, dorsal dermis and brown
adipose tissue (BAT). Intriguingly, it has been shown that BAT
arises from cells transiently expressing Myf5 (Seale et al., 2008).
The Myf5CreER strain could be used to determine at which devel-
opmental stage the progenitors giving rise to BAT are expressing
Myf5 and to investigate the relationship between these Myf5-
expressing cells and the progenitors in the dermomyotome.
TheMyf5CreER strain represents not only a useful tool for lineage
studies in which the fate of Myf5-expressing cells can be evaluated
in vivo, but also in studies in which the effects of the conditional
ablation of speciﬁc genes is evaluated. As opposed to strains
expressing CreER under the control of the Pax7 locus (Brack
et al., 2007; Lepper and Fan, 2010; Nishijo et al., 2009), the
Myf5CreER mice presented here could be employed to speciﬁcally
ablate gene expression only in the subpopulation of satellite cells
expressing Myf5 (Beauchamp et al., 2000; Gayraud-Morel et al.,
2012) or with a history of Myf5 expression (Kuang et al., 2007).
This could be particularly important to evaluate the molecular
basis of aspects of satellite cell heterogeneity. In this regard, as a
Fig. 6. Proposed lineage scheme for hindlimb muscles. Pax3+ve cells delaminate from the somitic dermomyotome and migrate into the limb buds, where they generate
embryonic myoblasts which terminally differentiate into primary ﬁbers. As development proceeds into the fetal stage, muscle stem cells resident in the limb activate the
expression of Pax7. Pax7+ve/MRF−ve progenitors remain throughout fetal myogenesis and after birth as source of myoblasts (fetal and postnatal) and possibly satellite cells.
During secondary myogenesis they generate fetal myoblasts by expressing Myf5 and other MRFs. Fetal Myf5+ve cells alternatively terminally differentiate during secondary
myogenesis or remain as committed, but undifferentiated cells until successive phases of muscle development. After birth they contribute to the pool myoblasts responsible
for postnatal growth and give rise to the majority of the adult satellite cells. A minority of the satellite cells resident in the adult limb muscles is derived from pericytes
present in the neonatal muscles and possibly from other postnatal stem cells. The dashed arrow indicates the still poorly deﬁned lineage relationship between embryonic
and fetal myoblasts. The red color and the weight of the arrows highlight the predominance of the lineage described in this study.
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allele (Gayraud-Morel et al., 2012), it is important to note that the
strategy adopted to generate the Myf5CreER strain does not disrupt
the coding region of the gene. Moreover, we were able to obtain
relatively high efﬁciencies of recombination in the satellite cell
compartment. Approximately 74% of satellite cells were marked by
5 consecutive injections of 2 mg of TMX in adult mice.
The expression of Myf5 has been reported only in approximately
90% of the satellite cells. The difference between the number of
satellite cells expressing Myf5 and those expressing the label is
likely resulting from incomplete CreER-mediated recombination.
Therefore, the efﬁciency of recombination appears to be more than
80%, which is comparable to the recombination obtained in
Pax7CreER mice (Nishijo et al., 2009), which have been successfully
employed to abolish gene expression in the satellite cell compart-
ment in several studies (Bjornson et al., 2012; Quach et al., 2009;
Shea et al., 2010). Potentially the efﬁciency of recombination
could be further improved by the removal of the neomycin-
coding cassette, as shown for the corresponding non-inducible,
Cre-recombinase-expressing mouse lines (Haldar et al., 2008).
In conclusion, we present data derived using a newly generated
Myf5CreER mouse strain to trace back the developmental time at
which the precursors of the satellite cells enter the myogenic
program through the induction of Myf5. This study suggests that
most of the satellite cells resident in adult hindlimb muscles are
likely to have activated Myf5 expression during fetal myogenesis,
and that it is the Myf5+ve fetal myoblast that is the primary
progenitor present during development that gives rise to the
satellite cell pool (Fig. 6).Acknowledgments
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